The Cell & Gene Meeting on the Mesa is the sector’s foremost annual conference bringing together senior executives and top decision-makers in the industry to advance cutting-edge research into cures. Cynata CEO Dr Kilian Kelly presented on Cynata’s Cymerus technology and provided an update on the Company’s robust clinical pipeline.
In case you missed it, Cynata CEO & MD Dr Kilian Kelly provided investors with an update on The Company’s ongoing active trials and its priorities for the next 12 months, including what investors should be looking for.
Watch his presentation below.
Following its strategic review, and off the back of two critical clinical trial updates - the opening of Cynata’s acute Graft-versus-host disease trial for enrolment and the approval of its Phase 1 clinical trial in kidney transplant patients - CEO Dr Kilian Kelly sat down with Kalkine Media to discuss the milestones.
Cynata has received regulatory approval from the Competent (regulatory) Authority in the Netherlands for a Phase 1 trial of CYP-001 in kidney transplant patients. Professor Rabelink, who is leading the trial, said it aims to alleviate anti-rejection drug side effects which would be of huge benefit to transplant patients as the side effects of immunosuppressants can be very devastating.
Listen to Cynata’s CEO and MD, Dr Kilian Kelly, provide an overview of the recently completed strategic review, and responses to investors’ questions.